EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing Therapeutics for Intratumoral Cancer Treatments: Antiproliferative Vanadium Complexes in Glioblastoma

Andrew C Bates iD, Kameron L Klugh, Anna O Galaeva, Raley A Patch, John F Manganaro, Skyler A Markham, Emma Scurek, Aviva Levina iD, Peter A Lay iD, Debbie C Crans iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26030994 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Andrew C Bates und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Colorado State University, Fort Collins, CO 80523, USA. Hauptthemen laut MEDLINE: Glioblastoma, Coordination Complexes, Antineoplastic Agents, Vanadium. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Colorado State University, Australian Research Council, Tour de Cure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma, an aggressive cancer, is difficult to treat due to its location, late detection, drug resistance, and poor absorption of chemotherapeutics. Intratumoral drug administration offers a promising potential treatment alternative with localized delivery and minimal systemic toxicity. Vanadium(V) coordination complexes, incorporating Schiff base and catecholate ligands, have shown effects as antiproliferative agents with tunable efficacy and reactivity, stability, steric bulk, hydrophobicity, uptake, and toxicity optimized for the intratumoral administration vehicle. A new series of oxovanadium(V) Schiff base–catecholate complexes were synthesized and characterized using nuclear magnetic resonance (NMR), UV-Vis, and infrared spectroscopy and mass spectrometry. Stability under physiological conditions was assessed via UV-Vis spectroscopy, and the antiproliferative activity was evaluated in T98G glioblastoma and SVG p12 normal glial cells using viability assays. The newly synthesized [VO(3-tBuHSHED)(TIPCAT)] complex was more stable (t1/2 ~4.5 h) and had strong antiproliferative activity (IC50 ~1.5 µM), comparing favorably with the current lead compound, [VO(HSHED)(DTB)]. The structural modifications enhanced stability, hydrophobicity, and steric bulk through substitution with iso-propyl and tert-butyl groups. The improved properties were attributed to steric hindrance associated with the new Schiff base and catecholato ligands, as well as the formation of non-toxic byproducts upon degradation. The [VO(3-tBuHSHED)(TIPCAT)] complex emerges as a promising candidate for glioblastoma therapy by demonstrating enhanced stability and a greater selectivity, which highlights the role of strategic ligand design in developing localized therapies for the treatment of resistant cancers. In reporting the new class of compounds effective against T98G glioblastoma cells, we describe the generally desirable properties that potential drugs being developed for intratumoral administration should have.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaCoordination ComplexesAntineoplastic AgentsVanadiumBrain NeoplasmsHumansCell ProliferationCell Line, TumorSchiff BasesCell Survival

Stichwörter der Autor:innen

cancerglioblastomahydrophobic Schiff base scaffoldinnovative chemotherapeutic agentsintratumoral injectionoptimizing drugs for intratumoral injectionoxovanadium Schiff base catecholate complexessterically hindered catecholvanadium

Substanzen

Coordination ComplexesAntineoplastic AgentsVanadiumSchiff Bases

Autor:innen und Institutionen

  • Department of Chemistry, Colorado State University, Fort Collins, CO 80523, USA.
  • School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
  • Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523, USA.

ORCID-Profile: Andrew C Bates, Aviva Levina, Peter A Lay, Debbie C Crans

Förderung

  • Colorado State University
  • Australian Research Council
  • Tour de Cure

Zitieren

APA

Bates, A. C., Klugh, K. L., Galaeva, A. O., Patch, R. A., Manganaro, J. F., Markham, S. A., Scurek, E., Levina, A., Lay, P. A., & Crans, D. C. (2025). Optimizing Therapeutics for Intratumoral Cancer Treatments: Antiproliferative Vanadium Complexes in Glioblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26030994

Vancouver

Bates AC, Klugh KL, Galaeva AO, Patch RA, Manganaro JF, Markham SA, et al. Optimizing Therapeutics for Intratumoral Cancer Treatments: Antiproliferative Vanadium Complexes in Glioblastoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26030994

BibTeX
@article{Bates2025,
  author = {Bates, Andrew C and Klugh, Kameron L and Galaeva, Anna O and Patch, Raley A and Manganaro, John F and Markham, Skyler A and Scurek, Emma and Levina, Aviva and Lay, Peter A and Crans, Debbie C},
  title = {Optimizing Therapeutics for Intratumoral Cancer Treatments: Antiproliferative Vanadium Complexes in Glioblastoma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26030994}
}
Kostenlos starten →